特立帕肽对老年髋部骨折保守治疗患者骨膜蛋白与骨密度的影响及意义(1)
【摘要】 目的 探討特立帕肽对老年女性髋部骨折保守治疗患者血清骨膜蛋白和骨密度的影响及意义。方法 80例老年女性股骨粗隆间骨折行保守治疗的患者为研究对象， 按照随机数字表法分为治疗组和对照组， 每组40例。对照组给予常规保守治疗， 治疗组在对照组基础上给予特立帕肽治疗。于治疗前， 治疗后第3、6、12个月时分别观察治疗组疼痛情况。于治疗前， 治疗后第1、2、3、6个月时分别进行血清骨膜蛋白水平、骨硬化蛋白水平、骨代谢指标及骨密度的检测比较。分析治疗组治疗6个月后骨膜蛋白、骨硬化蛋白及骨密度的相关性。结果 ①治疗组治疗后第3、6、12个月时患者疼痛数字评分法(NRS)评分均较治疗前下降， 差异均具有统计学意义(t=5.446、8.495、9.247， P<0.05)。②治疗组治疗后第1、2、3、6个月血清骨膜蛋白水平逐渐上升(9.3%、12.9%、15.8%、14.5%)， 均明显高于治疗前， 差异均有统计学意义(P<0.05)。③治疗组治疗后第1、2个月腰椎骨密度较治疗前无明显变化， 差异均无统计学意义(P>0.05);治疗后第3、6个月， 腰椎骨密度较治疗前分别提高10.6%、13.6%， 差异均具有统计学意义 (P<0.05)。④骨膜蛋白与骨密度呈显著正相关(r=0.567， P<0.01)， 与骨硬化蛋白呈显著负相关(r=-0.677， P<0.01);骨硬化蛋白与骨密度呈显著负相关(r=-0.396， P<0.05)。结论 特立帕肽能显著提高老年髋部骨折保守治疗患者的血清骨膜蛋白及骨密度， 可能发挥着促进骨折愈合的作用。
【关键词】 特立帕肽; 髋部骨折; 骨膜蛋白;骨密度
DOI：10.14163/j.cnki.11-5547/r.2019.19.007
【Abstract】 Objective To discuss the effect and significance of tripeptide on periosteal protein and bone mineral density in elderly patients with hip fracture treated conservatively. Methods A total of 80 elderly female patients with femoral intertrochanteric fracture treated conservatively as study subjects were divided by random number table method into treatment group and control group， with 40 cases in each group. The control group received conservative therapy， and the treatment group received tripeptide on the basis of the control group. The pain of the treatment group was observed before treatment and 3， 6 and 12 months after treatment. The levels of serum periosteal protein， osteosclerosis protein， bone metabolism index and bone mineral density were measured and compared before treatment and 1， 2， 3 and 6 months after treatment. The correlation of periosteal protein， osteosclerosis protein and bone mineral density was analyzed after 6 months of treatment in the treatment group. Results ①After 3， 6 and 12 months of treatment， the treatment group had lower numerical rating scale (NRS) score than those before treatment， and the difference was statistically significant (t=5.446， 8.495， 9.247， P<0.05). ②The treatment group had gradually increased levels of serum periosteal protein after 1， 2， 3 and 6 months of treatment (9.3%， 12.9%， 15.8% and 14.5%) than those before treatment. Their difference was statistically significant (P<0.05).③The treatment group had no obviously change in lumbar vertebral bone mineral density after 1 and 2 months of treatment， and the difference was not statistically significant (P>0.05). After 3 and 6 months of treatment， the lumbar vertebral bone mineral density increased by 10.6% and 13.6% respectively， and the difference was statistically significant (P<0.05). ④Periosteal protein was positively correlated with bone mineral density (r=0.567， P<0.01)， negatively correlated with osteosclerosis protein (r=-0.677， P<0.01)， and negatively correlated with bone mineral density (r=-0.396， P<0.05). Conclusion Tripeptide can significantly increase serum periosteal protein and bone mineral density in elderly patients with hip fracture treated conservatively， and it may play a role in promoting fracture healing., 百拇医药(黄文显 刘颗星 胡健辉 邓颂波 曾日祥 叶燕彬)
【关键词】 特立帕肽; 髋部骨折; 骨膜蛋白;骨密度
DOI：10.14163/j.cnki.11-5547/r.2019.19.007
【Abstract】 Objective To discuss the effect and significance of tripeptide on periosteal protein and bone mineral density in elderly patients with hip fracture treated conservatively. Methods A total of 80 elderly female patients with femoral intertrochanteric fracture treated conservatively as study subjects were divided by random number table method into treatment group and control group， with 40 cases in each group. The control group received conservative therapy， and the treatment group received tripeptide on the basis of the control group. The pain of the treatment group was observed before treatment and 3， 6 and 12 months after treatment. The levels of serum periosteal protein， osteosclerosis protein， bone metabolism index and bone mineral density were measured and compared before treatment and 1， 2， 3 and 6 months after treatment. The correlation of periosteal protein， osteosclerosis protein and bone mineral density was analyzed after 6 months of treatment in the treatment group. Results ①After 3， 6 and 12 months of treatment， the treatment group had lower numerical rating scale (NRS) score than those before treatment， and the difference was statistically significant (t=5.446， 8.495， 9.247， P<0.05). ②The treatment group had gradually increased levels of serum periosteal protein after 1， 2， 3 and 6 months of treatment (9.3%， 12.9%， 15.8% and 14.5%) than those before treatment. Their difference was statistically significant (P<0.05).③The treatment group had no obviously change in lumbar vertebral bone mineral density after 1 and 2 months of treatment， and the difference was not statistically significant (P>0.05). After 3 and 6 months of treatment， the lumbar vertebral bone mineral density increased by 10.6% and 13.6% respectively， and the difference was statistically significant (P<0.05). ④Periosteal protein was positively correlated with bone mineral density (r=0.567， P<0.01)， negatively correlated with osteosclerosis protein (r=-0.677， P<0.01)， and negatively correlated with bone mineral density (r=-0.396， P<0.05). Conclusion Tripeptide can significantly increase serum periosteal protein and bone mineral density in elderly patients with hip fracture treated conservatively， and it may play a role in promoting fracture healing., 百拇医药(黄文显 刘颗星 胡健辉 邓颂波 曾日祥 叶燕彬)